A5103157315- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Radiomics and Machine Learning in Medical Imaging
- Pancreatic and Hepatic Oncology Research
- Lung Cancer Diagnosis and Treatment
- Lymphoma Diagnosis and Treatment
Abstract Tumor mutational burden (TMB) in circulating tumor DNA (ctDNA) has shown promise predicting benefit from PD-L1/PD-1 inhibitors retrospective studies. Aiming to assess blood TMB (bTMB) prospectively, we conducted B-F1RST ( NCT02848651 ), an open-label, phase 2 trial that evaluated bTMB as a predictive biomarker for first-line atezolizumab monotherapy locally advanced or metastatic stage IIIB–IVB non-small cell lung cancer n = 152). The co-primary endpoints were investigator-assessed...
Tumor mutational burden (TMB) is being explored as a predictive biomarker for cancer immunotherapy outcomes in non-small cell lung cancer. BFAST (NCT03178552)-an open-label, global, multicohort trial-evaluated the safety and efficacy of first-line targeted therapies or patients with unresectable Stage IIIB IV advanced metastatic who were selected status using blood-based next-generation sequencing. In Phase 3 cohort C evaluating (b)TMB atezolizumab efficacy, bTMB ≥10 (N = 471) randomized 1:1...
Although comprehensive biomarker testing is recommended for all patients with advanced/metastatic non-small cell lung cancer (NSCLC) before initiation of first-line treatment, tissue availability can limit testing. Genomic in liquid biopsies be utilized to overcome the inherent limitations sampling and identify most appropriate biomarker-informed treatment option patients. The Blood First Assay Screening Trial a global, open-label, multicohort trial that evaluates efficacy safety multiple...
Abstract Background: Patients with the same disease stage and other clinical parameters often have markedly different prognoses display variable responses to standard treatments, even within oncogenic subsets. This variability may be driven by molecular heterogeneity mutational complexity that captured signatures potential for impact on patient management. Methods: BFAST (NCT03178552) is a Phase II/III global, multicenter, open-label, multi-cohort screening interventional umbrella trial...
LBA9023 Background: Tissue-based biomarker testing remains challenging as tumor biopsies are often inadequate for comprehensive and repeat can be risky in pts with advanced/metastatic NSCLC. These challenges could overcome by using blood-based to identify the most appropriate targeted therapy. BFAST (NCT03178552) is a global open-label, multicohort trial evaluating efficacy safety of selected therapies NSCLC harboring actionable genetic alterations, identified next-generation sequencing...
TPS8605 Background: Durvalumab following chemoradiation (CRT) is a standard of care for unresectable stage III NSCLC, but there remains an unmet need improved therapeutic options among patients with driver-mutated tumors that are unresponsive to immunotherapy. As targeting specific driver mutations (e.g. ALK, RET, ROS1) has proven effective in the metastatic setting, it hypothesized outcomes could also be NSCLC. Methods: BO42777 (NCT05170204) phase I–III platform study evaluating safety and...
TPS8608 Background: Targeting of oncogenic driver alterations has proven to be an effective clinical approach across many tumor types. As a result the approval targeted therapies against alterations, molecular biomarker testing is commonly recommended for patients with advanced/metastatic non-small cell lung cancer (NSCLC) before initiation first-line treatment. Although there are emerging trial data using in early-stage NSCLC, currently not universally performed as part routine practice...
AMA Dziadziuszko R, Peled N, Mok T, et al. High-dose alectinib for RET fusion-positive non-small cell lung cancer in the Blood First Assay Screening Trial. Contemporary Oncology/Współczesna Onkologia. 2024. doi:10.5114/wo.2023.135246. APA Dziadziuszko, R., Peled, N., Mok, T., Peters, S., Ponce Aix, & Alatorre-Alexander, J. (2024). https://doi.org/10.5114/wo.2023.135246 Chicago Rafal, Nir Tony Solange Santiago Jorge and Brian D. Vicuna "High-dose Trial". Harvard J., Vicuna, B., Maclennan, M.,...